Channel: Life Science Connect clear
| # | Channel | Title | Views | Likes | Cmts | Score | Sentiment | Duration | Transcript | Link |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Life Science Connect | Why iPSC is Research Thriving | 20 | 1 | 53.7 | 4:51 | All right, we have a lot to get through today, so let's get started. And I'd like to kick off our conversation under the scientific and clinical translation topic. And so to kick things off, Julie, I'd love for you to please walk us through why IPSE therapies have become such a compelling area of research and development and perhaps what makes this approach so exciting and why there are so many, why so many in the field are turning their attention to it as a potential, you know, game changer in the treatment landscape. Oh, Julie, I think you might be on mute. Thank you, Aaron. I'm really, really appreciate being here. I'm excited to be able to have the discussion today with you and Aaron Kimberl. And just want to say it's such an exciting space right now. There's a lot of groundbreaking advancement for regenerative medicine, biotherapeutics in general, especially at our center for regenerative biotherapeutics. We're working on a lot of different applications. But I think most of all, if you think about it at a high level, it's the versatility and accessibility of these cells, opportunities to not only use them as patient specific, but also an allogeneic source. The immune cloaking has really come along. There's a lot of applications. We see it moving into clinic for allogeneic use. And this is a game changer potentially for patients not to require immune suppression. I'm super excited about that. Not only in treatment such as diabetes, but also looking at tissue engineered organs in the future. And then targeting these complex diseases, looking at diabetes, multiple strokes, cardiac conditions that normally doesn't, does not have a specific treatment or a cure. So these cells can differentiate. It's very exciting looking at the diabetes space, possibly differentiate into beta, alpha delta to complete the islet is a huge opportunity. So I think it can have a global impact on patient health care. And it could be accessible, so democratized as a therapy to transform healthcare at a global scale. So there's a lot of interest in it, a lot of excitement, a lot of tools coming on board. And I think investors are extremely interested as well. Good, good, great. And a lot of what you mentioned today, especially the allogeneic approaches are definitely going to be part of our conversation. In fact, in leading up to today's discussion, our registrants have submitted some questions and some topics and the allogeneic approaches are certainly something they want us to cover, which we will. But before we do, Erin, I'd love to hear from you your perspective on why I, excuse me, IPSC therapies have become such a compelling area of research and development. And from your perspective, and your tenure, and even at Estellus, what are you seeing? Yeah, thanks for the question. First of all, yeah, thanks so much for your program and for inviting us here to talk about this. It truly is an exciting time. So I think when you look at the value proposition of using IPS cells as a starting material, their flurry coat in nature means that they have the ability to both self-renew and differentiate into a wide variety of cell type. And then, the new old property really means that you can expand them practically to unlimited amounts. So you have that same starting material that can be replenished. And then their ability to differentiate into all cell types in the body means that we have a great opportunity to develop a wide variety of therapeutic cell types, as Julie mentioned, so many different clinical applications. And I think that this is very helpful when you can have that consistent starting material from the same pool of cells. And you don't have to deal with the donor to donor variability or the exhaustion potential because you can simply go back and use that same replenishable starting material. So I think it's a really versatile tool that we can use for cell based therapies. And then in just thinking about the value proposition of cell based therapies, in many cases where tissues or cell types in the body have degenerated due to injury or disease, the only thing you can do to help patients in those situations is to replace the missing cell type or to provide a more sophisticated therapeutic entity. And I think there's a lot of advantages to using cells for patients with high-end metamine. | ↗ |